Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

被引：0
|
作者：
Christian Zurth
Mikko Koskinen
Robert Fricke
Olaf Prien
Timo Korjamo
Kristina Graudenz
Karsten Denner
Michaela Bairlein
Clemens-Jeremias von Bühler
Gary Wilkinson
Hille Gieschen
机构：
[1] Bayer AG,
[2] Orion Corporation,undefined
[3] Orion Pharma,undefined
[4] Bayer AG,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2019年 / 44卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：747 / 759
页数：12
相关论文
共 50 条
  • [1] Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
    Zurth, Christian
    Koskinen, Mikko
    Fricke, Robert
    Prien, Olaf
    Korjamo, Timo
    Graudenz, Kristina
    Denner, Karsten
    Bairlein, Michaela
    Von Buehler, Clemens-Jeremias
    Wilkinson, Gary
    Gieschen, Hille
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (06) : 747 - 759
  • [2] CLINICAL RELEVANCE OF DRUG-DRUG INTERACTIONS WITH DAROLUTAMIDE
    Floyd, Rebecca
    Sutton, Jennifer
    Olivier, Kara
    Zurth, Christian
    Smith, Matthew R.
    Shore, Neal
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [3] Maraviroc:: in vitro assessment of drug-drug interaction potential
    Hyland, Ruth
    Dickins, Maurice
    Collins, Claire
    Jones, Hannah
    Jones, Barry
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (04) : 498 - 507
  • [4] In Vitro Evaluation of the Drug Interaction Potential of Doravirine
    Bleasby, Kelly
    Fillgrove, Kerry L.
    Houle, Robert
    Lu, Bing
    Palamanda, Jairam
    Newton, Deborah J.
    Lin, Meihong
    Chan, Grace Hoyee
    Sanchez, Rosa, I
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (04)
  • [5] Toxicokinetics of β-Amanitin in Mice and In Vitro Drug-Drug Interaction Potential
    Bang, Young Yoon
    Song, Im-Sook
    Lee, Min Seo
    Lim, Chang Ho
    Cho, Yong-Yeon
    Lee, Joo Young
    Kang, Han Chang
    Lee, Hye Suk
    PHARMACEUTICS, 2022, 14 (04)
  • [6] Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.
    Zurth, Christian
    Graudenz, Kristina
    Denner, Karsten
    Korjamo, Timo
    Fricke, Robert
    Wilkinson, Gary
    Seitz, Friedeborg
    Prien, Olaf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] In vitro drug interaction studies in drug discovery - Higher throughput methods
    Johnson, D
    Janiszewski, J
    Tweedle, D
    PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON LABORATORY AUTOMATION AND ROBOTICS 1996, 1997, : 496 - 496
  • [8] In-vitro drug-drug interaction studies of diltiazem with floroquinolones
    Shafi, Nighat
    Siddiqui, Farhan Ahmed
    Arayne, Muhammad Saeed
    Sultana, Najma
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2017, 40 (20) : 1003 - 1014
  • [9] In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers
    Lu, Jinmiao
    Tian, Xusheng
    Tang, Dong
    Zhou, Xinyi
    Xu, Zengyan
    Ding, Juping
    Wang, Tong
    Yu, Qiang
    Ding, Jinsong
    XENOBIOTICA, 2021, 51 (10) : 1122 - 1131
  • [10] Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)
    Zurth, C. R.
    Fizazi, K.
    Fricke, R.
    Gieschen, H.
    Graudenz, K.
    Koskinen, M.
    Ploeger, B. A.
    Prien, O.
    Smith, M. R.
    Tammela, T.
    Shore, N. D.
    ANNALS OF ONCOLOGY, 2019, 30
12345